Additional details regarding the potential sale of the business are set forth in the Company's Form 8-K filed today.
About Vitaros ® and the Canadian ED Market
According to IMS Health data, the annual ED market in Canada in 2010 was approximately $180 million (CAD). The current leading medications are sildenafil citrate, tadalafil and vardenafil HCI which are taken in pill form and work by inhibiting an enzyme called PDE5.
There is still a need for new, safe and effective treatments, however, especially for those patients who cannot or do not respond well to oral medications. Vitaros
is applied topically which helps to reduce side effects and offers men who do not do well with the existing oral drugs a patient-friendly alternative. When absorbed through the skin, Vitaros
directly boosts blood flow, thereby causing an erection within minutes -- much faster than the results achieved from the oral medications.
The key innovation behind Vitaros
was combining alprostadil with Apricus Bio's NexACT
drug delivery technology. The NexACT
technology allows the drug to pass through the skin and makes the treatment much easier to apply and provides patients with a relatively safer alternative treatment because it avoids certain complications that can be associated with oral products.
In clinical studies, Vitaros
showed efficacy in patients suffering from mild to severe ED, including men who did not respond to sildenafil citrate. The side effects reported were localized and transient.
About Femprox ®
is a product candidate for the treatment of FSAD. Nine clinical studies have been successfully completed to date, including one, 98-subject Phase II study in the US and a nearly 400-subject Phase III study in China. To date, no product has been approved to treat FSAD, a persistent or recurring inability to attain or maintain adequate sexual excitement, causing personal distress. Estimates of the FSAD market size put it on par with ED in males.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. is a pharmaceutical company that develops and markets innovative treatments that help large patient populations across numerous, large-market therapeutic classes including male and female sexual health. Apricus Bio is headquartered in San Diego, California and is publicly traded on the NASDAQ Capital Market under the ticker symbol APRI.